[go: up one dir, main page]

GB201009891D0 - Fas (Apo-1, CD95) modified particles are novel therapeutic platforms for intacellular drug delivery - Google Patents

Fas (Apo-1, CD95) modified particles are novel therapeutic platforms for intacellular drug delivery

Info

Publication number
GB201009891D0
GB201009891D0 GBGB1009891.1A GB201009891A GB201009891D0 GB 201009891 D0 GB201009891 D0 GB 201009891D0 GB 201009891 A GB201009891 A GB 201009891A GB 201009891 D0 GB201009891 D0 GB 201009891D0
Authority
GB
United Kingdom
Prior art keywords
intacellular
apo
fas
drug delivery
novel therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1009891.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Priority to GBGB1009891.1A priority Critical patent/GB201009891D0/en
Priority to JP2012521104A priority patent/JP5754740B2/en
Priority to US13/386,349 priority patent/US11369572B2/en
Priority to EP10735082A priority patent/EP2456468A1/en
Priority to CN201080041671.2A priority patent/CN102497886B/en
Priority to PCT/GB2010/051207 priority patent/WO2011010156A1/en
Publication of GB201009891D0 publication Critical patent/GB201009891D0/en
Ceased legal-status Critical Current

Links

GBGB1009891.1A 2009-07-21 2010-06-14 Fas (Apo-1, CD95) modified particles are novel therapeutic platforms for intacellular drug delivery Ceased GB201009891D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1009891.1A GB201009891D0 (en) 2010-06-14 2010-06-14 Fas (Apo-1, CD95) modified particles are novel therapeutic platforms for intacellular drug delivery
JP2012521104A JP5754740B2 (en) 2009-07-21 2010-07-21 FAS (Apo-1, CD95) targeting platform for intracellular drug delivery
US13/386,349 US11369572B2 (en) 2009-07-21 2010-07-21 Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
EP10735082A EP2456468A1 (en) 2009-07-21 2010-07-21 Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
CN201080041671.2A CN102497886B (en) 2009-07-21 2010-07-21 Fas(Apo-1, CD95) targeting platform for intracellular drug delivery
PCT/GB2010/051207 WO2011010156A1 (en) 2009-07-21 2010-07-21 Fas (apo-1, cd95) targeted platforms for intracellular drug delivery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1009891.1A GB201009891D0 (en) 2010-06-14 2010-06-14 Fas (Apo-1, CD95) modified particles are novel therapeutic platforms for intacellular drug delivery

Publications (1)

Publication Number Publication Date
GB201009891D0 true GB201009891D0 (en) 2010-07-21

Family

ID=42471585

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1009891.1A Ceased GB201009891D0 (en) 2009-07-21 2010-06-14 Fas (Apo-1, CD95) modified particles are novel therapeutic platforms for intacellular drug delivery

Country Status (1)

Country Link
GB (1) GB201009891D0 (en)

Similar Documents

Publication Publication Date Title
EP2718317A4 (en) Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
IL231009A (en) Bicyclic heteroaromatic compounds, their preparation and pharmaceutical compositions containing them
EP2629786A4 (en) Compositions for drug administration
GB2491327B (en) Delayed prolonged drug delivery
HUE042850T2 (en) Compositions for drug delivery
IL223116A0 (en) Dose counters for inhalers, inhalers andshafts thereof
PT2648699T (en) Tamper-resistant dosage form
IL225824A0 (en) Quinoxaline derivatives, their preparation and pharmaceutical compositions containing them
ZA201209739B (en) Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof
PL2616133T3 (en) Devices for transdermal drug delivery
IL232035A (en) Heterocyclic compounds, such compounds as medicaments and pharmaceutical compositions comprising them
IL230463A (en) Benzamides, their preparation and pharmaceutical compositions containing them
HUE062316T2 (en) Drug delivery technology
IL226094A0 (en) Pyrazine derivatives, their preparation and pharmaceutical compositions containing them
GB201121476D0 (en) Novel pharmaceutical formulation
IL223872A (en) Pyrazoloquinolines and intermediate compounds, process for their preparation, use thereof and medicaments and pharmaceutical compositions comprising them
EP2618816A4 (en) Aerosol composition for administering drugs
SI2793857T1 (en) Drug delivery technology
SG10201606838VA (en) Infusion preparation
ZA201302012B (en) Low dose pharmaceutical composition
EP2692337A4 (en) Film-shaped externally used drug composition
GB201110632D0 (en) Drug delivery formulations
PL2806880T5 (en) Pharmaceutical composition as a substance for antireflux antacid drug
GB201009891D0 (en) Fas (Apo-1, CD95) modified particles are novel therapeutic platforms for intacellular drug delivery
GB0912645D0 (en) fas (apo-1, cd95) modified particles are novel therapeutic platforms for intracellular drug delivery

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)